Central Nervous System Involvement in Peripheral T Cell Lymphoma.

Area of Science:

• Oncology
• Neurology
• Hematology

Background:

• Central nervous system (CNS) involvement in peripheral T cell lymphoma (PTCL) is a challenging clinical scenario.
• Primary CNS lymphoma (PCNSL) within PTCL is rare (2% of PCNSLs), while CNS relapse occurs in 2-6% of PTCL cases.
• Extranodal involvement is a risk factor for CNS relapse, and prophylactic treatment lacks consensus.

Purpose of the Study:

• To review the current understanding and treatment of CNS involvement in PTCL.
• To highlight the limitations of existing therapeutic approaches.
• To emphasize the need for novel treatment strategies.

Main Methods:

• Review of existing literature on CNS involvement in PTCL.
• Analysis of treatment outcomes and toxicities.
• Identification of risk factors for CNS relapse.

Main Results:

• High-dose systemic methotrexate-based regimens are standard but toxic, particularly for elderly patients.
• Consolidation with high-dose chemotherapy and autologous stem cell transplantation is used but also carries toxicity.
• No established consensus exists for CNS prophylactic treatment indications.

Conclusions:

• Current treatments for CNS PTCL are associated with significant toxicity, limiting their use in vulnerable populations.
• There is a critical unmet need for safer and more effective therapeutic approaches for CNS PTCL.
• Further research into novel agents and strategies is essential to improve outcomes for patients with CNS involvement in PTCL.